Search

Your search keyword '"Krause V"' showing total 20 results
Start Over Author "Krause V" Publisher elsevier bv
20 results on '"Krause V"'

1. Otitis media at 6-monthly assessments of Australian First Nations children between ages 12–36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines

Author

Leach, A.J., primary, Wilson, N., additional, Arrowsmith, B., additional, Beissbarth, J., additional, Mulholland, E.K., additional, Santosham, M., additional, Torzillo, P.J., additional, McIntyre, P., additional, Smith-Vaughan, H., additional, Skull, S.A., additional, Oguoma, V.M., additional, Chatfield, M., additional, Lehmann, D., additional, Binks, M.J., additional, Licciardi, P.V., additional, Andrews, R., additional, Snelling, T., additional, Krause, V., additional, Carapetis, J., additional, Chang, A.B., additional, and Morris, P.S., additional

Published
2023
Full Text
View/download PDF

2. Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.

Author

Leach, AJ, Mulholland, EK, Santosham, M, Torzillo, PJ, McIntyre, P, Smith-Vaughan, H, Wilson, N, Arrowsmith, B, Beissbarth, J, Chatfield, MD, Oguoma, VM, Licciardi, P, Skull, S, Andrews, R, Carapetis, J, McDonnell, J, Krause, V, Morris, PS, Leach, AJ, Mulholland, EK, Santosham, M, Torzillo, PJ, McIntyre, P, Smith-Vaughan, H, Wilson, N, Arrowsmith, B, Beissbarth, J, Chatfield, MD, Oguoma, VM, Licciardi, P, Skull, S, Andrews, R, Carapetis, J, McDonnell, J, Krause, V, and Morris, PS

Abstract

BACKGROUND: Aboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. We compared immunogenicity (ELISA and opsonophagocytic activity) of a combination of Synflorix™ (PHiD-CV10, 10 serotypes and protein D of NTHi) and Prevenar13™ (PCV13, 10 serotypes plus 3, 6A, and 19A), with recommended schedules. METHODS: This open-label superiority trial randomised (1:1:1) Aboriginal infants at 28 to 38 days of age, to PCV13 (P) at 2-4-6 months (_PPP), PHiD-CV10 (S) at 2-4-6 months (_SSS), or PHiD-CV10 at 1-2-4 plus PCV13 at -6 months (SSSP). Primary outcomes (blinded) were immunogenicity against PCV13-only serotypes 3, 6A, 19A, and PHiD-CV10-only protein D at 7 months. Secondary outcomes include immunogenicity against all serotypes at 2, 4 and 7 months. FINDINGS: Between 2011 and 2017, 425 infants were allocated to _PPP(143), _SSS(141) or SSSP(1 4 1). An intention to treat approach including all available data was used. The SSSP group had superior immunogenicity against serotypes 3, 6A, and 19A compared to _SSS (OPA GMT ratios 8.1 to 59.5, p < 0.001), and against protein D compared to _PPP (GMC ratio 11.9 (95%CI 9.7 to 14.6)). Immune responses to protein D and 3, 6A, and 19A in SSSP were not significantly lower (i.e. no harm) than either _SSS or _PPP. For ten common serotypes responses at 2, 4 and 7 months were superior for SSSP (following 1-, 2-, and 4- doses) than _SSS and _PPP (following 0-, 1-, and 3- doses). At 4 months, _SSS was superior to _PPP. Reactogenicity and hospitalisations were rare and unrelated to the intervention. INTERPRETATION: From two months, the 1-2-4-6-month combined schedule (SSSP) was safe and significantly more immunogenic than 2-4-6-month schedules. The earlier responses may be beneficial in high-risk populations.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results